Showing 1571-1580 of 2526 results for "".
- Heidelberg Engineering Receives European Acceptance for Spectralis Shift Technology Under New Medical Device Regulationhttps://modernod.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/Heidelberg Engineering announced the launch of the Spectralis platform with shift technology, which is designed to create synergies that significantly increase efficiency in both OCT and OCTA, and deliver images with more detail. Shift enables clinicians to switch between OCT scan
- In-Office MGD Procedure Market is Largely Untapped, Survey Showshttps://modernod.com/news/in-office-mgd-procedure-market-is-largely-untapped-survey-shows/2480424/Doctors in the US and Europe diagnose approximately two-thirds of their dry eye patients with evaporative dry eye but treat very few of them in the office for meibom
- Alcon Unveils SMART Solutions Integration and Connectivity Platform at AAO 2021https://modernod.com/news/alcon-unveils-latest-evolution-of-cataract-integration-and-connectivity-at-aao-2021/2480414/At the American Academy of Ophthalmology (AAO) 2021 annual meeting in New Orleans, Alcon will feature its latest advancement in integrated and connected surgical technologi
- Survey: Americans are Frustrated by Unexpected Blurry Near Vision Issueshttps://modernod.com/news/survey-americans-are-frustrated-by-unexpected-blurry-near-vision-issues/2480303/According to a recent survey commission
- IrisVision Unveils Streamlined, Lightweight New Design for Award-Winning Low Vision Headsethttps://modernod.com/news/irisvision-unveils-streamlined-lightweight-new-design-for-award-winning-low-vision-headset/2480294/
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Is Undergraduate Ophthalmology Teaching in the United Kingdom Still Fit for Purpose?https://modernod.com/news/is-undergraduate-ophthalmology-teaching-in-the-united-kingdom-still-fit-for-purpose/2479479/An editorial in the publication Eye examines the reasons behind why an increasing number of junior doctors and general practitioners in the UK are losing confidence in their ophthalmic knowledge. Such factors cited in the d
- Contact Lens Institute Unveils Nationwide “See Tomorrow Campaign;” Industry Launch Event Slated for July 22https://modernod.com/news/contact-lens-institute-unveils-nationwide-see-tomorrow-campaign-industry-launch-event-slated-for-july-22/2479347/A new professional and consumer initiative from the Contact Lens Institute (CLI) is poised to reveal insights about how patient psyches surrounding vision, health care and their lives have changed over the course of the pandemic—and the ensuing opportunities for the optometry community. The CLI <
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan
- Scientists Unravel the Function of a Sight-Saving Growth Factorhttps://modernod.com/news/scientists-unravel-the-function-of-a-sight-saving-growth-ffactor/2479302/Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-r